← Back to Changelog
Low mhra

Corporate report: MHRA-NICE Real-World Evidence Scientific Dialogue

Key Changes

  • Described as MHRA-NICE Real-World Evidence Scientific Dialogue programme
  • Stated to help decision making across the lifecycle of products
  • Stated to benefit both regulatory and health technology assessment (HTA) evaluations

Affected Roles

Regulatory AffairsHealth Technology Assessment (HTA)

Action Required

Original source must be reviewed before compliance decisions; suggest reviewing the programme description to assess potential relevance for regulatory and HTA evidence planning.